Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cellectis and VitamFero have entered into a five-year research, development and licensing agreement, under which Cellectis will license its proprietary meganuclease technology to VitamFero to design and develop new generation of living attenuated vaccines.
Subscribe to our email newsletter
As per the agreement, Cellectis is responsible for supplying preselected meganucleases to VitamFero to utilize in the development of vaccines against parasites responsible for toxoplasmosis, neosporosis, and others.
Cellectis CEO Andre Choulika said they are delighted to be working with VitamFero in this field to promote the development of a new application of our technology.
VitamFero CEO Pascal Breton said this agreement represents an important step forward for their company, by getting access to Cellectis’ intellectual propriety and strengthening their technological potential in the modification of the genomes of apicomplex parasites.